{"title":"Estudio comparativo de la capacidad de aprendizaje de ChatGPT en la resolución de preguntas de especialización médica","authors":"Álvaro Fuentes-Martín , Ángel Cilleruelo-Ramos , Bárbara Segura-Méndez , Julio Mayol","doi":"10.1016/j.opresp.2024.100340","DOIUrl":"10.1016/j.opresp.2024.100340","url":null,"abstract":"","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 ","pages":"Article 100340"},"PeriodicalIF":0.0,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000432/pdfft?md5=3908709d1fe87e91a5c3fe61cf5dca13&pid=1-s2.0-S2659663624000432-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141406038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-20DOI: 10.1016/j.opresp.2024.100336
Oscar Perez , Miguel Santibañez , Laura Rasines , Jose Maria Castillo , Adrian Hugo Aginagalde-Llorente
Objective
To characterize long-term patient-reported symptoms and quality of life, in adults after COVID-19.
Material and methods
Cross-sectional study in Cantabria (Northern Spain) including adults with PCR-confirmed SARS-CoV-2 infection (n = 694) with a time period between 4.7 and 24 month post-SARS-CoV-2 diagnosis, and their close contacts (n = 663) (PCR negative and without suspected infection) obtained from simple random sampling of a total of 47,773 cases and 94,301 close contacts. The ISARIC survey was used as screening tool with self-reported “non-feeling fully recovery (NFFR)” defined as primary outcome.
Results
16.57% (n = 115/694) reported NFFR. Most prevalent symptoms were in order of frequency: Fatigue (54.8%); Loss of smell (40.9%); Problems speaking or communicating (29.6%); Loss of taste (28.7%); Confusion/lack of concentration (27.8%); Persistent muscle pain (24.3%) and Shortness of breath/breathlessness (23.5%). When comparing the three ordinal groups (Close contacts, COVID-19 feeling recovered, and COVID-19 NFFR) the prevalence of these symptoms was increasingly higher among each ordinal group (p < 0.001). Female gender was significantly associated with NFFR: (adjusted odds ratio (aOR) = 1.56); as well as older age: aOR per 10 year increment = 1.15. Lastly, they scored on average 9.63 points less in Euroquol.
Conclusions
More than 15% of patients in our real-life population-based study, reported NFFR, being female sex and older age independent predictors of this condition. Most symptoms in these patients were in accordance with WHO definition of post COVID-19 condition in adults, and were less prevalent in COVID-19 feeling recovered and close contact respectively, with a statistically significant dose-response pattern, and with a large decrease in quality of life according to Euroquol.
{"title":"Long-Term Patient Symptoms and Quality of Life in Adults After COVID-19: A Real Life Study","authors":"Oscar Perez , Miguel Santibañez , Laura Rasines , Jose Maria Castillo , Adrian Hugo Aginagalde-Llorente","doi":"10.1016/j.opresp.2024.100336","DOIUrl":"10.1016/j.opresp.2024.100336","url":null,"abstract":"<div><h3>Objective</h3><p>To characterize long-term patient-reported symptoms and quality of life, in adults after COVID-19.</p></div><div><h3>Material and methods</h3><p>Cross-sectional study in Cantabria (Northern Spain) including adults with PCR-confirmed SARS-CoV-2 infection (<em>n</em> <!-->=<!--> <!-->694) with a time period between 4.7 and 24 month post-SARS-CoV-2 diagnosis, and their close contacts (<em>n</em> <!-->=<!--> <!-->663) (PCR negative and without suspected infection) obtained from simple random sampling of a total of 47,773 cases and 94,301 close contacts. The ISARIC survey was used as screening tool with self-reported “non-feeling fully recovery (NFFR)” defined as primary outcome.</p></div><div><h3>Results</h3><p>16.57% (<em>n</em> <!-->=<!--> <!-->115/694) reported NFFR. Most prevalent symptoms were in order of frequency: Fatigue (54.8%); Loss of smell (40.9%); Problems speaking or communicating (29.6%); Loss of taste (28.7%); Confusion/lack of concentration (27.8%); Persistent muscle pain (24.3%) and Shortness of breath/breathlessness (23.5%). When comparing the three ordinal groups (Close contacts, COVID-19 feeling recovered, and COVID-19 NFFR) the prevalence of these symptoms was increasingly higher among each ordinal group (<em>p</em> <!--><<!--> <!-->0.001). Female gender was significantly associated with NFFR: (adjusted odds ratio (aOR)<!--> <!-->=<!--> <!-->1.56); as well as older age: aOR per 10 year increment<!--> <!-->=<!--> <!-->1.15. Lastly, they scored on average 9.63 points less in Euroquol.</p></div><div><h3>Conclusions</h3><p>More than 15% of patients in our real-life population-based study, reported NFFR, being female sex and older age independent predictors of this condition. Most symptoms in these patients were in accordance with WHO definition of post COVID-19 condition in adults, and were less prevalent in COVID-19 feeling recovered and close contact respectively, with a statistically significant dose-response pattern, and with a large decrease in quality of life according to Euroquol.</p></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 3","pages":"Article 100336"},"PeriodicalIF":0.0,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000390/pdfft?md5=ffac87a94aba520d23ebc6c5e97620c6&pid=1-s2.0-S2659663624000390-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141134495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-20DOI: 10.1016/j.opresp.2024.100335
Alba Naya Prieto , Carlos López Chang , María del Pilar Carballosa de Miguel , Miren Itziar Fernández Ormaechea , María de los Ángeles Zambrano Chacón , Luis Jiménez Hiscock , Germán Peces-Barba Romero , María Jesús Rodríguez Nieto , Sarah Beatriz Heili Frades
{"title":"High-Flow Oxygen: Respiratory Mechanics in Lung Alveoli of Patients After Acute Respiratory Failure","authors":"Alba Naya Prieto , Carlos López Chang , María del Pilar Carballosa de Miguel , Miren Itziar Fernández Ormaechea , María de los Ángeles Zambrano Chacón , Luis Jiménez Hiscock , Germán Peces-Barba Romero , María Jesús Rodríguez Nieto , Sarah Beatriz Heili Frades","doi":"10.1016/j.opresp.2024.100335","DOIUrl":"10.1016/j.opresp.2024.100335","url":null,"abstract":"","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 3","pages":"Article 100335"},"PeriodicalIF":0.0,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000389/pdfft?md5=215aad90b6fa2072c664a30f7a23b912&pid=1-s2.0-S2659663624000389-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141139628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-15DOI: 10.1016/j.opresp.2024.100334
Myriam Aburto , José Antonio Rodríguez-Portal , Estrella Fernandez-Fabrellas , Raquel García Sevila , Susana Herrera Lara , Elena Bollo de Miguel , José María González Ruiz , María Molina-Molina , Belén Safont Muñoz , Raul Godoy Mayoral , Ana Dolores Romero Ortiz , María José Soler Sempere , Diego Castillo Villegas , Javier Gaudó Navarro , Laura Tomás López , Belén Nuñez Sanchez , Zulema Palacios Hidalgo , Jacobo Sellares Torres , Lirios Sacristán Bou , María Asunción Nieto Barbero , Claudia Valenzuela
Objective
The objective of the study was to analyze the diagnostic process and the time until the start of treatment of patients with idiopathic pulmonary fibrosis in relation to the publication of successive clinical practice guide.
Material and methods
Multicenter, observational, ambispective study, in which patients includes in the idiopathic pulmonary fibrosis registry of the Spanish Society of Pulmonologist and Thoracic Surgery were analyzed. An electronic data collection notebook was enabled on the society's website. Sociodemographic and clinical variables were collected at diagnosis and follow-up of the patients.
Results
From January 2012 to december 2019, 1064 patients were included in the registry, with 929 finally analyzed. The diagnosis process varied depending on the year in which it was performed, and the radiological pattern observed in the high-resolution computed tomography. Up to 26.3% of the cases (244) were diagnosed with chest high-resolution computed tomography and clinical evaluation. Surgical biopsy was used up to 50.2% of cases diagnosed before 2011, while it has been used in 14.2% since 2018. The median time from the onset of symptoms to diagnosis was 360 days (IQR 120-720), taking more than 2 years in the 21.0% of patients. A percentage of 79.4 of patients received antifibrotic treatment. The average time from diagnosis to the antifibrotic treatment has been 309 ± 596.5 days, with a median of 49 (IQR 0-307).
Conclusions
The diagnostic process, including the time until diagnosis and the type of test used, has changed from 2011 to 2019, probably due to advances in clinical research and the publication of diagnostic-therapeutic consensus guidelines.
{"title":"Influencia de las guías de práctica clínica en el diagnóstico y tratamiento de la fibrosis pulmonar idiopática. Datos del Registro de la Sociedad Española de Neumología y Cirugía Torácica","authors":"Myriam Aburto , José Antonio Rodríguez-Portal , Estrella Fernandez-Fabrellas , Raquel García Sevila , Susana Herrera Lara , Elena Bollo de Miguel , José María González Ruiz , María Molina-Molina , Belén Safont Muñoz , Raul Godoy Mayoral , Ana Dolores Romero Ortiz , María José Soler Sempere , Diego Castillo Villegas , Javier Gaudó Navarro , Laura Tomás López , Belén Nuñez Sanchez , Zulema Palacios Hidalgo , Jacobo Sellares Torres , Lirios Sacristán Bou , María Asunción Nieto Barbero , Claudia Valenzuela","doi":"10.1016/j.opresp.2024.100334","DOIUrl":"10.1016/j.opresp.2024.100334","url":null,"abstract":"<div><h3>Objective</h3><p>The objective of the study was to analyze the diagnostic process and the time until the start of treatment of patients with idiopathic pulmonary fibrosis in relation to the publication of successive clinical practice guide.</p></div><div><h3>Material and methods</h3><p>Multicenter, observational, ambispective study, in which patients includes in the idiopathic pulmonary fibrosis registry of the Spanish Society of Pulmonologist and Thoracic Surgery were analyzed. An electronic data collection notebook was enabled on the society's website. Sociodemographic and clinical variables were collected at diagnosis and follow-up of the patients.</p></div><div><h3>Results</h3><p>From January 2012 to december 2019, 1064 patients were included in the registry, with 929 finally analyzed. The diagnosis process varied depending on the year in which it was performed, and the radiological pattern observed in the high-resolution computed tomography. Up to 26.3% of the cases (244) were diagnosed with chest high-resolution computed tomography and clinical evaluation. Surgical biopsy was used up to 50.2% of cases diagnosed before 2011, while it has been used in 14.2% since 2018. The median time from the onset of symptoms to diagnosis was 360 days (IQR 120-720), taking more than 2 years in the 21.0% of patients. A percentage of 79.4 of patients received antifibrotic treatment. The average time from diagnosis to the antifibrotic treatment has been 309<!--> <!-->±<!--> <!-->596.5 days, with a median of 49 (IQR 0-307).</p></div><div><h3>Conclusions</h3><p>The diagnostic process, including the time until diagnosis and the type of test used, has changed from 2011 to 2019, probably due to advances in clinical research and the publication of diagnostic-therapeutic consensus guidelines.</p></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 3","pages":"Article 100334"},"PeriodicalIF":0.0,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000377/pdfft?md5=3830c625fed73c227b9b6ede3894cb8e&pid=1-s2.0-S2659663624000377-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141031678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Continuous Positive Airway Pressure (CPAP) constitutes the most effective treatment for Obstructive Sleep Apnea (OSA). Automatic titration systems (ATS) are predominantly used to achieve adaptation to the equipment. Home CPAP devices allow telemonitoring (TM) of the same parameters as those provided by ATS but with access to continuous usage data. Under this premise, we conducted a study on the potential validity of TM for home CPAP devices as a titration system, its direct impact on proper adaptation (AD) to the equipment, and secondarily on the healthcare resources employed to achieve it.
Material and methods
An observational study involving 318 patients with OSA who were titrated using TM to achieve AD to CPAP. Patients with OSA were consecutively recruited and evaluated at 1, 3, and 6 months after initiating treatment. Results were compared with a historical group of 307 patients with OSA who achieved AD to CPAP using ATS. Additionally, we assessed the impact on required healthcare resources.
Results
Patients with OSA who initiated CPAP treatment with TM over the first six months showed a similar AD rate compared to the historical group titrated using ATS, with lower resource usage in the TM group.
Conclusion
Data provided by TM of home CPAP devices allow for titration and achieving similar AD as with ATS in non-complex patients.
导言持续气道正压(CPAP)是治疗阻塞性睡眠呼吸暂停(OSA)最有效的方法。自动滴定系统(ATS)主要用于实现对设备的适应。家用 CPAP 设备可以远程监控 (TM) 与自动滴定系统提供的参数相同的参数,但可以获取连续使用数据。在此前提下,我们对家用 CPAP 设备的 TM 作为滴定系统的潜在有效性、其对设备适当适应性(AD)的直接影响,以及其次对实现该目标所使用的医疗资源进行了研究。连续招募 OSA 患者,并在开始治疗后的 1、3 和 6 个月进行评估。我们将结果与 307 名使用 ATS 实现 AD 到 CPAP 的 OSA 患者进行了比较。此外,我们还评估了对所需医疗资源的影响。结果在最初 6 个月内开始使用 TM 进行 CPAP 治疗的 OSA 患者的 AD 率与使用 ATS 进行滴定的历史组相似,而 TM 组的资源使用率较低。
{"title":"Impacto de la telemonitorización como sistema para una adecuada titulación y adaptación de la CPAP domiciliaria en la apnea obstructiva del sueño (proyecto T-CPAP)","authors":"María Teresa Ramírez Prieto, M.a Vaneas Lores Gutiérrez, Raul Moreno Zabaleta, Rocío Rodríguez Pérez","doi":"10.1016/j.opresp.2024.100332","DOIUrl":"10.1016/j.opresp.2024.100332","url":null,"abstract":"<div><h3>Introduction</h3><p>Continuous Positive Airway Pressure (CPAP) constitutes the most effective treatment for Obstructive Sleep Apnea (OSA). Automatic titration systems (ATS) are predominantly used to achieve adaptation to the equipment. Home CPAP devices allow telemonitoring (TM) of the same parameters as those provided by ATS but with access to continuous usage data. Under this premise, we conducted a study on the potential validity of TM for home CPAP devices as a titration system, its direct impact on proper adaptation (AD) to the equipment, and secondarily on the healthcare resources employed to achieve it.</p></div><div><h3>Material and methods</h3><p>An observational study involving 318 patients with OSA who were titrated using TM to achieve AD to CPAP. Patients with OSA were consecutively recruited and evaluated at 1, 3, and 6 months after initiating treatment. Results were compared with a historical group of 307 patients with OSA who achieved AD to CPAP using ATS. Additionally, we assessed the impact on required healthcare resources.</p></div><div><h3>Results</h3><p>Patients with OSA who initiated CPAP treatment with TM over the first six months showed a similar AD rate compared to the historical group titrated using ATS, with lower resource usage in the TM group.</p></div><div><h3>Conclusion</h3><p>Data provided by TM of home CPAP devices allow for titration and achieving similar AD as with ATS in non-complex patients.</p></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 ","pages":"Article 100332"},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000353/pdfft?md5=c001b26994f59ef46a186a6b0fa06801&pid=1-s2.0-S2659663624000353-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141035367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-08DOI: 10.1016/j.opresp.2024.100331
Javier Dominguez-Ortega , Xavier Muñoz-Gall , Julio Delgado-Romero , Francisco Casas-Maldonado , Marina Blanco-Aparicio
{"title":"Challenges in the Implementation of the Spanish Consensus on the Reduction of Oral Corticosteroids: Insights From the Medical Community","authors":"Javier Dominguez-Ortega , Xavier Muñoz-Gall , Julio Delgado-Romero , Francisco Casas-Maldonado , Marina Blanco-Aparicio","doi":"10.1016/j.opresp.2024.100331","DOIUrl":"10.1016/j.opresp.2024.100331","url":null,"abstract":"","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 3","pages":"Article 100331"},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000341/pdfft?md5=9e63cafc19aa117ceb3a4a2787cca217&pid=1-s2.0-S2659663624000341-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141051194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-01DOI: 10.1016/j.opresp.2024.100333
Eva Tabernero Huguet
{"title":"Avances y desafíos en el control de la tuberculosis multirresistente (TB-MDR)","authors":"Eva Tabernero Huguet","doi":"10.1016/j.opresp.2024.100333","DOIUrl":"10.1016/j.opresp.2024.100333","url":null,"abstract":"","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 3","pages":"Article 100333"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000365/pdfft?md5=fb2a097b60061ff6e683dd5e48c684a7&pid=1-s2.0-S2659663624000365-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141028055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}